Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mh, Kranenborg"'
Autor:
Oc, Boerman, Mh, Kranenborg, Oosterwijk E, Gl, Griffiths, Wj, Mcbride, Wim J.G. Oyen, de Weijert M, Oosterwijk-Wakka J, Hj, Hansen, Fh, Corstens
Publikováno v:
Europe PubMed Central
Radiolabeled monoclonal antibodies (mAbs) can target tumors selectively. Sustained activity levels in nontarget tissues limit their application. Pretargeting approaches using bispecific mAbs (bsmAbs) or the biotinavidin interaction have been proposed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cd21f8624c7d492e87535489eb52195b
https://pubmed.ncbi.nlm.nih.gov/10485489
https://pubmed.ncbi.nlm.nih.gov/10485489
Publikováno v:
Europe PubMed Central
Antibodies accumulate nonspecifically in infectious foci due to the locally increased vascular permeability. This study describes a method of infection imaging in which 99mTc-DTPA (diethylenetriaminepentaacetic acid) is trapped at the target by a pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d4eb09b237c8bd247c386a9f1cb3200e
https://pubmed.ncbi.nlm.nih.gov/9189139
https://pubmed.ncbi.nlm.nih.gov/9189139
Autor:
Boerman OC; Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands. O.Boerman@nugen.azn.nl, Kranenborg MH, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJ, de Weijert M, Oosterwijk-Wakka J, Hansen HJ, Corstens FH
Publikováno v:
Cancer research [Cancer Res] 1999 Sep 01; Vol. 59 (17), pp. 4400-5.
In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Autor:
Steffens MG; Department of Urology, University Hospital Nijmegen, The Netherlands., Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, Boerman OC
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 1999 May; Vol. 40 (5), pp. 829-36.
Autor:
Steffens MG; Department of Urology, University Hospital Nijmegen, The Netherlands. m.steffens@nugen.azn.nl, Kranenborg MH, Boerman OC, Zegwaart-Hagemeier NE, Debruyne FM, Corstens FH, Oosterwijk E
Publikováno v:
Cancer biotherapy & radiopharmaceuticals [Cancer Biother Radiopharm] 1998 Apr; Vol. 13 (2), pp. 133-9.
Autor:
Kranenborg MH; Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands. H.Kranenborg@nugen.azn.nl, Boerman OC, Oosterwijk-Wakka JC, de Weijert MC, Corstens FH, Oosterwijk E
Publikováno v:
International journal of cancer [Int J Cancer] 1998 Jan 05; Vol. 75 (1), pp. 74-80.
Autor:
Kranenborg MH; Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands., Boerman OC, de Weijert MC, Oosterwijk-Wakka JC, Corstens FH, Oosterwijk E
Publikováno v:
Cancer [Cancer] 1997 Dec 15; Vol. 80 (12 Suppl), pp. 2390-7.
Autor:
Kranenborg MH; Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands., Oyen WJ, Corstens FH, Oosterwijk E, van der Meer JW, Boerman OC
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 1997 Jun; Vol. 38 (6), pp. 901-6.
Autor:
Kranenborg MH; Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands., Boerman OC, Oosterwijk-Wakka JC, de Weijert MC, Corstens FH, Oosterwijk E
Publikováno v:
Cancer research [Cancer Res] 1995 Dec 01; Vol. 55 (23 Suppl), pp. 5864s-5867s.
Autor:
van Duijnhoven JL; Department of Biochemistry, University of Nijmegen, The Netherlands., Schalkwijk J, Kranenborg MH, van Vlijmen-Willems IM, Groeneveld A, van Erp PE, Timmer ED, de Jongh GJ, van de Ven WJ
Publikováno v:
Archives of dermatological research [Arch Dermatol Res] 1992; Vol. 284 (3), pp. 167-72.